Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOD1 | Q9Y239 | 7/20 | 0.56 |
| ▸ | GLP1R | P43220 | 7/20 | 0.43 |
| ▸ | GNPAT | O15228 | 1/20 | 0.43 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.43 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19034951 | 0.92 | NOD1 (0.58) | NOD1GLP1RGNPATSLC6A5FOLH1 | |
| SCHEMBL21242878 | 0.92 | NOD1 (0.65) | NOD1GNPATSLC6A5FOLH1 | |
| SCHEMBL21242888 | 0.92 | NOD1 (0.65) | NOD1GNPATSLC6A5FOLH1 | |
| SCHEMBL19752290 | 0.92 | NOD1 (0.65) | NOD1GNPATSLC6A5FOLH1 | |
| SCHEMBL23689917 | 0.92 | NOD1 (0.65) | NOD1GNPATSLC6A5FOLH1 | |
| SCHEMBL24558577 | 0.92 | NOD1 (0.65) | NOD1GNPATSLC6A5FOLH1 | |
| SCHEMBL21242828 | 0.92 | NOD1 (0.65) | NOD1GNPATSLC6A5FOLH1 | |
| SCHEMBL23689916 | 0.92 | NOD1 (0.65) | NOD1GNPATSLC6A5FOLH1 | |
| SCHEMBL12674214 | 0.92 | NOD1 (0.65) | NOD1GNPATSLC6A5FOLH1 | |
| SCHEMBL14553069 | 0.92 | NOD1 (0.65) | NOD1GNPATSLC6A5FOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230287051-A1 | INHIBITORS OF COMPLEMENT FACTOR C3 AND THEIR MEDICAL USES | ZEALAND PHARMA A/S (DK) | 2023-09-14 | — | — | US | disclosed |
| EP-2758426-B1 | NOVEL GLUCAGON ANALOGUES | NOVO NORDISK AS (DK) | 2019-08-07 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230287051-A1 | INHIBITORS OF COMPLEMENT FACTOR C3 AND THEIR MEDICAL USES | CFB, C9, CFH | NOD1 1126/4885GLP1R 3100/4885GNPAT 3378/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.